Zoster vaccine in immunocompromised patients: Time to reconsider current recommendations

Clinical Infectious Diseases

Volumn 59, Issue 7, 2014, Pages 920-922

  Oxman, Michael N ^a,b   Schmader, Kenneth E ^c,d  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer chemotherapy; Herpes zoster; Immunization; Varicella zoster virus; Zoster vaccine

Indexed keywords

VARICELLA ZOSTER VACCINE; ANTINEOPLASTIC AGENT;

ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; ELECTRONIC HEALTH RECORD; EMERGENCY WARD; HEALTH CARE SYSTEM; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INCIDENCE; NOTE; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; VACCINATION; COMPLICATION; FEMALE; IMMUNOLOGY; MALE; NEOPLASM;

ANTINEOPLASTIC AGENTS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; NEOPLASMS;

EID: 84925882955     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu501     Document Type: Note

References (12)

1. Tseng HF, Tartof S, Harpaz R, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis 2014; 59:913-9.
2. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30.
3. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
4. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and postherpetic neuralgia in an older US population: a cohort study. PLoS Med 2013; 10: e1001420.
5. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308:43-9.
6. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737-44.
7. Pergam SA, Forsberg CW, Boeckh MJ, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis 2011; 13: 15-23.
8. Habel LA, Ray GT, Silverberg MJ, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev 2013; 22:82-90.
9. Centers for Disease Control and Prevention. Noninfluenza vaccination coverage among adults - United States, 2012. Morb Mortal Wkly Rep 2014; 63:95-102.
10. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200:1068-77.
11. Benson CA, Hua L, Andersen J, et al. ZOSTAVAX is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial. In: 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, WA. Abstract 96.
12. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010; 51:197-213.